High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. 2019

Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.

Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-related substrates, contributing to DNA repair in the Fanconi anemia pathway. Also, numerous evidences reported that UBE2T is closely related to cell proliferation and carcinogenesis. However, the relationship between MM and UBE2T has not been studied. Here, we integrated eight datasets and analyzed the relationship of expression of UBE2T and ISS, 1q21, relapse and survival in MM 2684 patients (totally 2893 samples). We found that the expression of UBE2T increased with the deterioration of MM (P = 1.4e-07), especially in the early stage. UBE2T is closely related to IgG serotype MM (P = 6.9e-05). High expression of UBE2T is associated with poor survival and prognosis (EFS: P = 1.43e-03, OS: P = 5.47e-05). UBE2T is likely to play a part in the cell division pathway, affecting the survival and prognosis of MM. Therefore, UBE2T could be considered as an early alternative biomarker for the prognosis of MM.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D044763 Ubiquitin-Conjugating Enzymes A class of enzymes that form a thioester bond to UBIQUITIN with the assistance of UBIQUITIN-ACTIVATING ENZYMES. They transfer ubiquitin to the LYSINE of a substrate protein with the assistance of UBIQUITIN-PROTEIN LIGASES. Ubiquitin-Conjugating Enzyme,HHR6 Protein,Ubiquitin-Conjugating Enzyme E2,E2, Ubiquitin-Conjugating Enzyme,Enzyme E2, Ubiquitin-Conjugating,Enzyme, Ubiquitin-Conjugating,Enzymes, Ubiquitin-Conjugating,Ubiquitin Conjugating Enzyme,Ubiquitin Conjugating Enzyme E2,Ubiquitin Conjugating Enzymes

Related Publications

Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
March 2024, Cancer cell international,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
June 2023, International journal of laboratory hematology,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
January 2022, BioMed research international,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
July 2023, Genes & genomics,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
February 2016, British journal of cancer,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
January 2021, Cancer biomarkers : section A of Disease markers,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
April 2019, Bioscience reports,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
November 2022, Expert review of hematology,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
August 2021, The pharmacogenomics journal,
Weilong Zhang, and Ye Zhang, and Zuozhen Yang, and Xiaoni Liu, and Ping Yang, and Jing Wang, and Kai Hu, and Xue He, and Xiuru Zhang, and Hongmei Jing
January 2020, Journal of Cancer,
Copied contents to your clipboard!